Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

doi:10.1136/bmj.38050.674826.AE

BMJ 2004;328:989-990 (24 April), doi:10.1136/bmj.38050.674826.AE (published 19 March 2004)

Paper

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

Patricia Yudkin, reader¹, Marcus Munafò, research fellow², Kate Hey, research officer², Sarah Roberts, research nurse², Sarah Welch, research nurse², Elaine Johnstone, research fellow², Michael Murphy, director², Siân Griffiths, scientific officer², Robert Walton, senior research fellow²

¹ Department of Primary Health Care, University of Oxford, Oxford OX3 7LF, ² Cancer Research UK General Practice Research Group, Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE

Correspondence to: P Yudkin pat.yudkin@dphpc.ox.ac.uk

The first 150 words of the full text of this article appear below.

Introduction

The overall effectiveness of nicotine replacement therapy couldbe greater if the therapy were targeted at those most likelyto respond. Variants of the dopamine D2 receptor (DRD2 32806C/T) have been implicated in the initiation and maintenanceof smoking,^1
2 and these variants may also be related to responseto nicotine replacement therapy.³ Additionally, mechanisms ofnicotine addiction may differ in men and women.⁴ With this evidencein mind, we examined whether the response to nicotine replacementtherapy is modified by sex and genotype.

Participants, methods, and results

A randomised controlled trial of nicotine patches in 1991-2recruited 1686 heavy smokers ( $>=$ 15 cigarettes aday).⁵ The participants wore patches for 12 weeks. Abstinencefrom smoking was confirmed at one week by expired carbon monoxideconcentration $<=$ 10 ppm, and at 12, 24, and 52 weeks by salivarycotinine concentration $<=$ 20 ng/ml (89% of cases) or by expiredcarbon monoxide concentration $<=$ 10 ppm.

In . . . [Full text of this article]

Comment

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Articles

Nicotine replacement therapy in pregnancy: Tim Coleman, John Britton, and Jim Thornton
BMJ 2004 328: 965-966. [Extract] [Full Text] [PDF]

Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study: Richard P Sargent, Robert M Shepard, and Stanton A Glantz
BMJ 2004 328: 977-980. [Abstract] [Full Text] [PDF]

Mortality among "never smokers" living with smokers: two cohort studies, 1981-4 and 1996-9: Sarah Hill, Tony Blakely, Ichiro Kawachi, and Alistair Woodward
BMJ 2004 328: 988-989. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

Zuo, Y., Gilbert, D. G., Rabinovich, N. E., Riise, H., Needham, R., Huggenvik, J. I. (2009). DRD2-related TaqIA polymorphism modulates motivation to smoke. Nicotine Tob Res 11: 1321-1329 [Abstract] [Full text]
Munafo, M. R., Johnstone, E. C., Murphy, M. F. G., Aveyard, P. (2009). Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res 11: 404-407 [Abstract] [Full text]
Quaak, M., van Schayck, C. P., Knaapen, A. M., van Schooten, F. J. (2009). Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. Eur Respir J 33: 468-480 [Abstract] [Full text]
Munafo, M. R., Timpson, N. J., David, S. P., Ebrahim, S., Lawlor, D. A. (2009). Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res 0: ntn012v1-ntn012 [Abstract] [Full text]
Uhl, G. R., Liu, Q.-R., Drgon, T., Johnson, C., Walther, D., Rose, J. E., David, S. P., Niaura, R., Lerman, C. (2008). Molecular Genetics of Successful Smoking Cessation: Convergent Genome-Wide Association Study Results. Arch Gen Psychiatry 65: 683-693 [Abstract] [Full text]
Munafo, M. R., Johnstone, E. C., Murphy, M. F.G., Aveyard, P. (2008). "Intention to Analyze" in Pharmacogenomics Studies. Cancer Epidemiol. Biomarkers Prev. 17: 740-741 [Full text]
Woolf, S. H. (2007). Priorities to Improve Health Outcomes--Reply. JAMA 297: 2346-2347 [Full text]
Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F.G., Walton, R. T., Munafo, M. R. (2007). Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial. Cancer Epidemiol. Biomarkers Prev. 16: 1065-1069 [Abstract] [Full text]
Carlsten, C., Burke, W. (2006). Potential for Genetics to Promote Public Health: Genetics Research on Smoking Suggests Caution About Expectations. JAMA 296: 2480-2482 [Full text]
Lee, A. M., Tyndale, R. F. (2006). Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 20: 7-14 [Abstract]
Munafo, M. R., Johnstone, E. C., Wileyto, E. P., Shields, P. G., Elliot, K. M., Lerman, C. (2006). Lack of Association of 5-HTTLPR Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial.. Cancer Epidemiol. Biomarkers Prev. 15: 398-400 [Full text]
Berrettini, W. H., Lerman, C. E. (2005). Pharmacotherapy and Pharmacogenetics of Nicotine Dependence. Am. J. Psychiatry 162: 1441-1451 [Abstract] [Full text]
Lerman, C., Patterson, F., Berrettini, W. (2005). Treating Tobacco Dependence: State of the Science and New Directions. JCO 23: 311-323 [Abstract] [Full text]
O'Gara, C. (2004). Pharmacogenetics and addiction services. Psychiatr. Bull. 28: 426-427 [Full text]

Rapid Responses:

Read all Rapid Responses

Reply to: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial: Pamela R. Fung, et al.
bmj.com, 21 May 2004 [Full text]